



PHARMACEUTICALS

VOLUME 100 A
A REVIEW OF HUMAN CARCINOGENS

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008

LYON, FRANCE - 2012

IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE.....	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION.....	14
1. Exposure data.....	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References	31
GENERAL REMARKS	33
BUSULFAN.....	39
1. Exposure Data	39
1.1 Identification of the agent.....	39
1.2 Use of the agent	39
2. Cancer in Humans.....	40
3. Cancer in Experimental Animals	41
4. Other Relevant Data	41
4.1 Absorption, distribution, metabolism, and excretion.....	41
4.2 Genotoxic effects	42
4.3 Mechanisms of carcinogenesis	43
4.4 Synthesis.....	43
5. Evaluation	43
References	43

CHLORAMBUCIL	47
1. Exposure Data	47
1.1 Identification of the agent.....	47
1.2 Use of the agent	47
2. Cancer in Humans.....	48
2.1 Cancers following treatment for various diseases.....	48
2.2 Cancers following treatment for chronic lymphocytic leukaemia	49
3. Cancer in Experimental Animals	49
4. Other Relevant Data	52
4.1 Absorption, distribution, metabolism, and excretion.....	52
4.2 Genotoxic effects	52
4.3 Synthesis.....	53
5. Evaluation	53
References	53
METHYL-CCNU	57
1. Exposure Data	57
1.1 Identification of the agent.....	57
1.2 Use of the agent	57
2. Cancer in Humans.....	58
3. Cancer in Experimental Animals	58
4. Other Relevant Data	58
4.1 Absorption, distribution, metabolism, and excretion.....	58
4.2 Genotoxic effects	59
4.3 Mechanisms of carcinogenesis	60
4.4 Synthesis.....	60
5. Evaluation	60
References	60
CYCLOPHOSPHAMIDE	63
1. Exposure Data	63
1.1 Identification of the agent.....	63
1.2 Use of the agent	63
2. Cancer in Humans.....	66
2.1 Synthesis.....	67
3. Cancer in Experimental Animals	67
4. Other Relevant Data	73
4.1 Absorption, distribution, metabolism, and excretion.....	73
4.2 Genetic and related effects.....	73
4.3 Mechanisms of carcinogenesis	77
4.4 Synthesis.....	82
5. Evaluation	82
References	83
ETOPOSIDE IN COMBINATION WITH CISPLATIN AND BLEOMYCIN	91
1. Exposure Data	91
1.1 Identification of the agent.....	91
1.2 Use of the agents	92

2. Cancer in Humans.....	95
3. Cancer in Experimental Animals	99
4. Other Relevant Data	99
4.1 Absorption, distribution, metabolism, and excretion.....	99
4.2 Mechanisms of carcinogenesis	99
4.3 Synthesis.....	101
5. Evaluation	101
References	102
MELPHALAN	107
1. Exposure Data	107
1.1 Identification of the agent.....	107
1.2 Use of the agent	107
2. Cancer in Humans.....	108
3. Cancer in Experimental Animals	109
4. Other Relevant Data	109
4.1 Absorption, distribution, metabolism, and excretion.....	109
4.2 Mechanisms of carcinogenesis	112
4.3 Synthesis.....	113
5. Evaluation	113
References	113
MOPP	119
1. Exposure Data	119
1.1 Identification of the agent.....	119
1.2 Use of the combination.....	121
2. Cancer in Humans.....	121
2.1 Acute myeloid leukaemia.....	121
2.2 Cancer of the lung.....	122
2.3 Other sites	122
3. Cancer in Experimental Animals	123
4. Other Relevant Data	123
4.1 Synthesis.....	126
5. Evaluation	126
References	126
TAMOXIFEN	131
1. Exposure Data	131
1.1 Identification of the agent.....	131
1.2 Use of the agent	132
2. Cancer in Humans.....	133
2.1 Cancer of the endometrium.....	133
2.2 Contralateral breast cancer.....	135
2.3 Chemoprevention of cancer of the breast	135
2.4 Gastrointestinal cancers	136
2.5 Cancer of the ovary.....	136
2.6 Synthesis.....	136

3. Cancer in Experimental Animals	137
3.1 Oral administration.....	137
3.2 Subcutaneous administration	137
3.3 Perinatal administration	137
3.4 Administration with known carcinogens.....	148
3.5 Synthesis.....	148
4. Other Relevant Data	148
4.1 Absorption, distribution, metabolism, and excretion.....	148
4.2 Genetic and related effects.....	151
4.3 Synthesis.....	155
5. Evaluation	155
References	155
THIOTEPA.....	163
1. Exposure Data	163
1.1 Identification of the agent.....	163
1.2 Use of the agent	163
2. Cancer in Humans.....	164
3. Cancer in Experimental Animals	164
4. Other Relevant Data	166
4.1 Absorption, distribution, metabolism, and excretion.....	166
4.2 Genotoxic effects	166
4.3 Synthesis.....	168
5. Evaluation	168
References	168
TREOSULFAN.....	171
1. Exposure Data	171
1.1 Identification of the agent.....	171
1.2 Use of the agent	171
2. Cancer in Humans.....	172
3. Cancer in Experimental Animals	172
4. Other Relevant Data	172
4.1 Absorption, distribution, metabolism, and excretion.....	172
4.2 Genotoxic effects	172
4.3 Synthesis.....	173
5. Evaluation	173
References	173
DIETHYLSTILBESTROL.....	175
1. Exposure Data	175
1.1 Identification of the agent.....	175
1.2 Use of the agent	175
2. Cancer in Humans.....	177
2.1 Women exposed to diethylstilbestrol during pregnancy	177
2.2 Women exposed <i>in utero</i>	180

2.3	Men exposed to diethylstilbestrol.....	183
2.4	Offspring (third generation) of women who were exposed to diethylstilbestrol <i>in utero</i>	185
2.5	Synthesis.....	186
3.	Cancer in Experimental Animals	186
3.1	Oral administration.....	186
3.2	Subcutaneous and/or intramuscular administration	186
3.3	Subcutaneous implantation	190
3.4	Perinatal exposure.....	190
3.5	Synthesis.....	192
4.	Other Relevant Data	198
4.1	Absorption, distribution, metabolism, and excretion.....	198
4.2	Genetic and related effects.....	199
4.3	Synthesis.....	206
5.	Evaluation	206
	References	207
	ESTROGEN-ONLY MENOPAUSAL THERAPY.....	219
1.	Exposure Data	219
1.1	Identification of the agents.....	219
1.2	Use of the agents	223
2.	Cancer in Humans.....	227
2.1	Cancer of the breast.....	227
2.2	Cancer of the endometrium.....	228
2.3	Cancer of the colorectum.....	229
2.4	Cancer of the ovary.....	229
2.5	Cancer of the urinary bladder.....	230
2.6	Cancer of the pancreas.....	231
2.7	Exogenous estrogen use and melanoma risk.....	231
2.8	Cancer of the cervix	231
2.9	Cancer of the thyroid.....	231
2.10	Synthesis.....	231
3.	Cancer in Experimental Animals	232
3.1	Summary of the previous <i>IARC Monograph</i>	232
3.2	Studies published since the previous <i>IARC Monograph</i>	234
3.3	Synthesis.....	237
4.	Other Relevant Data	237
4.1	Absorption, distribution, metabolism, and excretion.....	237
4.2	Genetic and related effects.....	238
4.3	Synthesis.....	241
5.	Evaluation	241
	References	241
	COMBINED ESTROGEN-PROGESTOGEN MENOPAUSAL THERAPY	249
1.	Exposure Data	249
1.1	Identification of the agents.....	249
1.2	Use of the agents	255

2. Cancer in Humans.....	256
2.1 Cancer of the breast.....	256
2.2 Cancer of the endometrium.....	263
2.3 Cancer of the colorectum.....	264
2.4 Cancer of the ovary.....	265
2.5 Cancer of the skin.....	266
2.6 Cancer of the thyroid.....	267
2.7 Lymphomas and leukaemias.....	267
2.8 Cancers of the central nervous system.....	267
2.9 Cancer of the urinary tract.....	267
2.10 Cancer of the lung.....	268
2.11 Cancer of the pancreas.....	268
2.12 Cancer of the stomach.....	269
2.13 Cancer of the cervix.....	269
2.14 Cancer of the liver.....	269
2.15 Synthesis.....	269
3. Cancer in Experimental Animals.....	269
3.1 Summary of the previous <i>IARC Monograph</i>	269
3.2 Studies published since the previous <i>IARC Monograph</i>	270
4. Other Relevant Data.....	274
4.1 Absorption, distribution, metabolism, and excretion.....	274
4.2 Genetic and related effects.....	274
4.3 Synthesis.....	277
5. Evaluation.....	277
References.....	278

COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES 283

1. Exposure Data.....	283
1.1 Identification of the agents.....	283
1.2 Use of the agents.....	283
2. Cancer in Humans.....	286
2.1 Cancer of the breast.....	286
2.2 Cancer of the endometrium.....	291
2.3 Cancer of the cervix.....	292
2.4 Cancer of the ovary.....	293
2.5 Cancer of the liver.....	295
2.6 Cancer of the skin.....	296
2.7 Cancer of the colorectum.....	296
2.8 Cancer of the thyroid.....	297
2.9 Lymphomas.....	297
2.10 Cancers of the central nervous system.....	298
2.11 Cancer of the urinary tract.....	298
2.12 Cancer of the lung.....	299
2.13 Cancer of the pancreas.....	299
2.14 Cancer of the gallbladder.....	299
2.15 Cancer of the stomach.....	299

2.16 Other cancers	299
2.17 Synthesis	300
3. Cancer in Experimental Animals	300
3.1 Estrogen–progestogen combinations	300
3.2 Estrogens	302
3.3 Progestogens	303
3.4 Synthesis	304
4. Other Relevant Data	305
4.1 Absorption, distribution, metabolism, and excretion	305
4.2 Genetic and related effects	305
4.3 Synthesis	310
5. Evaluation	311
References	311
AZATHIOPRINE	319
1. Exposure Data	319
1.1 Identification of the agent	319
1.2 Use of the agent	319
2. Cancer in Humans	320
2.1 Transplant recipients	320
2.2 Autoimmune disorders	320
3. Cancer in Experimental Animals	321
4. Other Relevant Data	325
4.1 Absorption, distribution, metabolism, and excretion	325
4.2 Genotoxic effects	327
4.3 Mechanisms of carcinogenesis in organ-transplant patients	328
4.4 Synthesis	328
5. Evaluation	329
References	329
CHLORNAPHAZINE	333
1. Exposure Data	333
1.1 Identification of the agent	333
1.2 Use of the agent	333
2. Cancer in Humans	334
3. Cancer in Experimental Animals	334
4. Other Relevant Data	334
5. Evaluation	335
References	335
CICLOSPORIN	337
1. Exposure Data	337
1.1 Identification of the agent	337
1.2 Use of the agent	337
2. Cancer in Humans	339
3. Cancer in Experimental Animals	340

4. Other Relevant Data	341
4.1 Absorption, distribution, metabolism, and excretion.....	341
4.2 Cytogenetic effects.....	341
4.3 Mechanisms of carcinogenesis	341
4.4 Synthesis.....	343
5. Evaluation	343
References	343
PLANTS CONTAINING ARISTOLOCHIC ACID	347
1. Exposure Data	347
1.1 Identification of the agent.....	347
1.2 Use of the agent	348
2. Cancer in Humans.....	352
2.1 Case reports	352
2.2 Aristolochic acid nephropathy.....	352
3. Cancer in Experimental Animals	352
3.1 Aristolochic acid	352
3.2 Extracts from Aristolochia species.....	357
3.3 Herbal remedy containing aristolochic acids	358
4. Other Relevant Data	358
4.1 Absorption, distribution, metabolism, and excretion.....	358
4.2 Toxic effects	358
4.3 Genotoxic effects	358
4.4 Synthesis.....	359
5. Evaluation	359
References	360
METHOXSALEN PLUS ULTRAVIOLET A RADIATION	363
1. Exposure Data	363
1.1 Identification of the agent.....	363
1.2 Use of the agent	363
2. Cancer in Humans.....	364
2.1 Cohort studies	364
3. Cancer in Experimental Animals	366
3.1 Methoxsalen and UVA.....	366
3.2 Methoxsalen alone	366
4. Other Relevant Data	370
4.1 Absorption, distribution, metabolism and excretion	370
4.2 Mechanisms of carcinogenesis	371
4.3 Synthesis.....	372
5. Evaluation	372
References	373
PHENACETIN	377
1. Exposure Data	377
1.1 Identification of the agent.....	377

1.2 Use of the agent	377
2. Cancer in Humans.....	378
2.1 Case reports	378
2.2 Case-control studies.....	378
3. Cancer in Experimental Animals	388
3.1 Analgesic mixtures containing phenacetin	388
4. Other Relevant Data	394
4.1 Absorption, distribution, excretion, and metabolism.....	394
4.2 Genetic and related effects.....	394
5. Evaluation	395
References	395
LIST OF ABBREVIATIONS.....	399
CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS	403

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

